Skip to main content
Fig. 3 | Critical Care

Fig. 3

From: Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands

Fig. 3

Cost-effectiveness acceptability curve. This cost-effectiveness acceptability curve shows the probability that the use of PCT-guided antibiotic treatment is cost-effective compared to standard of care, for a willingness-to-pay threshold ranging from €0/quality-adjusted life year (QALY) to €200,000/QALY. This analysis incorporates all healthcare-related costs over a one-year time horizon

Back to article page

Critical Care

ISSN: 1364-8535